Dermatology Drugs Market (By Indication: Acne, Psoriasis, Rosacea, Alopecia, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies; By Administration Analysis: Topical Administration, Oral Administration, Parenteral Administration) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Dermatology Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Dermatology Drugs Market, by Indication, 2024-2033
8.1.1 Acne
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Psoriasis
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Rosacea
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Alopecia
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2033)
9.1. Dermatology Drugs Market, by Distribution Channel, 2024-2033
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Online Pharmacies
10.1. Dermatology Drugs Market, by Administration Analysis, 2024-2033
10.1.1. Topical Administration
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Oral Administration
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Parenteral Administration
11.1. North America
11.1.1. Market Revenue and Forecast, by Indication (2021-2033)
11.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Indication (2021-2033)
11.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Indication (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Indication (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Indication (2021-2033)
11.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Indication (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Indication (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Indication (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Indication (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Administration Analysis (2021-2033)
12.1. LUPIN (India)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis AG (Switzerland)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffmann-La Roche Ltd (Switzerland)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer Inc. (U.S.)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Sanofi (France)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Amgen inc. (U.S.)
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Lilly (U.S.)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. AstraZeneca (U.K.)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AbbVie Inc (U.S.)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Johnson & Johnson Private Limited (U.S.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample